Moehler, M <br/><br/>
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jun 2011 
 - 1358-1366 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdq591  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--administration & dosage<br/>Cetuximab<br/>Esophageal Neoplasms--drug therapy<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Irinotecan<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Stomach Neoplasms--drug therapy<br/>Treatment Outcome